Schildknecht S, Ullrich V
In the oral semaglutide administration group, the final doses were 3, 7, 14 mg in 10, 52, and 24 patients, respectively
massiliensis could account for 43% of high TMAO producers with 97% specificity
This represents the best-quality clinical evidence for DSIP, though the sample size was small Multi-species animal data -- DSIP has demonstrated sleep-promoting effects in rabbits, mice, rats, cats, and humans Stress modulation -- DSIP suppresses stress-induced cortisol and ACTH rises, potentially relevant for stress-related insomnia Opioid and alcohol withdrawal -- small studies explored DSIP as an adjunct in withdrawal management 2024 fusion peptide study -- published in Frontiers in Pharmacology, research on DSIP-BBB fusion peptides in insomnia mouse models represents renewed interest in DSIP Important limitations of DSIP's clinical evidence: Most studies are from the 1980s-1990s, conducted before modern polysomnography and sleep study methodology were standardized Sample sizes are consistently small Results are inconsistent across studies -- some show clear sleep effects while others do not No large-scale, placebo-controlled RCTs have been conducted Publication bias (positive results more likely published) may inflate the apparent evidence Side Effects Comparison# Cortistatin Side Effects# No human safety data exists
T2879), -aminobutyric acid (GABA, catalogue n
For most people, a dose between 250mg and 500mg provides a solid foundation for wellness, while those with higher stress levels or environmental exposure may benefit from up to 1,000mg
